Timing is everything: new study aims to perfect miscarriage treatment
NCT ID NCT07506512
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at the best time interval between two medications, mifepristone and misoprostol, for managing early pregnancy loss. Researchers will follow 1,000 participants to see which timing leads to the highest success rate with fewer side effects. The goal is to improve treatment and satisfaction for those experiencing this condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mifepristone and misoprostol
What this could lead to
If successful, this could establish a standard timing for these medications, improving treatment success and patient satisfaction for early pregnancy loss.
What could go wrong
This is a Phase 3 trial, but it's still testing timing, not a new drug. Results may vary by individual, and there are risks like bleeding or infection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY PREGNANCY LOSS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••